Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Calcipotriol hydrate (Daivonex; Dovonex; MC-903; PRI-2201; Psorcutan; Sorilux), is a synthetic analog of calcitriol/Vitamin D3 (VD3) and a strong agonist of the VD3 receptor (VDR). It is marketed under the trade name Dovonex and is used in the treatment of psoriasis. It is less than 1% as active as calcitriol in controlling calcium metabolism, but it has a similar affinity for the Vitamin D receptor (VDR) as calcitriol (Vit. D). Calcipotriol is primarily used in medicine to treat chronic plaque psoriasis. Alopecia areata has also been successfully treated with it.
Targets |
vitamin D receptor
|
---|---|
ln Vitro |
When NHEK cell cultures were stimulated with IL-17A or IL-22, capecitatriol either had no effect (2–20 nM) or modestly increased (0.2 nM) the expression of IL-8 mRNA. Our earlier research was validated by the addition of IL-17A and IL-22, which greatly raised the mRNA expression of IL-8. Doses of 2, 20, and 40 nM of calcipotriol monohydrate dye-wise blocked this increased expression of IL-8 mRNA [1]. Medication administration to natural killer (NK) cells can alter the NK cytotoxic uptake or KIR expression. In under four hours, human NK cells were treated with 100, 10, or 1 ng/mL of 1,25 (OH) 2D3, calcipotriol monohydrate, or FTY720. Four hours following amino acids, the expression of NKp30 on the surface of NK cells was considerably up-regulated by three doses of 1, 25 (OH) 2D3, calcipotriol monohydrate, and FTY720 [2].
|
ln Vivo |
All animals except for the diclofenac plus DFMO plus calcipotriol monohydrate group collapsed, and one of the thirty-two clofenac animals in each group perished. The groups were equally divided in terms of survival. When compared to gradient (linear regression model), body weight gain was significantly lower in the diclofenac plus calcipotriol monohydrate and diclofenac plus DFMO plus calcipotriol monohydrate treatment groups [3].
|
References |
[1]. Al-Jaderi Z, et al. Effects of vitamin D3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. Toxins (Basel). 2013 Oct 28;5(11):1932-47.
[2]. Sakabe JI, et al. Calcipotriol Increases hCAP18 mRNA Expression but Inhibits Extracellular LL37 Peptide Production in IL-17/IL-22-stimulated Normal Human Epidermal Keratinocytes. Acta Derm Venereol. 2014 Sep;94(5):512-6. [3]. Pommergaard HC, et al. Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. Anticancer Res. 2013 Aug;33(8):3033-9 |
Molecular Formula |
C27H42O4
|
---|---|
Molecular Weight |
430.6200
|
Exact Mass |
430.31
|
Elemental Analysis |
C, 75.31; H, 9.83; O, 14.86
|
CAS # |
147657-22-5
|
Related CAS # |
Calcipotriol;112965-21-6
|
Appearance |
Solid powder
|
SMILES |
C[C@H](/C=C/[C@H](C1CC1)O)[C@H]2CC[C@@H]\3[C@@]2(CCC/C3=C\C=C/4\C[C@H](C[C@@H](C4=C)O)O)C.O
|
InChi Key |
XBKHACNRWFKJNC-MANNPBRJSA-N
|
InChi Code |
InChI=1S/C27H40O3.H2O/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2;/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3;1H2/b13-6+,19-7+,21-10-;/t17-,22-,23-,24+,25-,26+,27-;/m1./s1
|
Chemical Name |
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol;hydrate
|
Synonyms |
MC-903; PRI 2201; Psorcutan; Sorilux; MC903; Calcitrene; CCRIS 7700; Daivonex; Dovonex; MC 903; Calcipotriene; Calcipotriol Monohydrate
|
HS Tariff Code |
2934.99.03.00
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. (3). This product is not stable in solution, please use freshly prepared working solution for optimal results. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~100 mg/mL (~232.2 mM)
Ethanol: ~100 mg/mL (~232.2 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 5 mg/mL (11.61 mM) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (11.61 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (11.61 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 2.5 mg/mL (5.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 7: 2.5 mg/mL (5.81 mM) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 8: ≥ 2.5 mg/mL (5.81 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3222 mL | 11.6112 mL | 23.2223 mL | |
5 mM | 0.4644 mL | 2.3222 mL | 4.6445 mL | |
10 mM | 0.2322 mL | 1.1611 mL | 2.3222 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Various concentrations of 1,25(OH)2D3, calcipotriol and FTY720 augment NK cells lysis of K562 target cells. E:T cell ratio shown is 2:1. Toxins (Basel) . 2013 Oct 28;5(11):1932-47. td> |
Treatment of mature DCs with the drugs modulates their surface expression. Mature DCs were incubated for either 4 h or 24 h with 100, 10 or 1 ng/mL of 1,25(OH)2D3, calcipotriol or FTY720, washed and then examined. Toxins (Basel) . 2013 Oct 28;5(11):1932-47. td> |